Trials / Terminated
TerminatedNCT02997189
Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss
A Multicenter, Randomized, Phase 2 Study to Assess the Feasibility, Safety and Efficacy of OTO-104 Given by Intratympanic Administration in Subjects at Risk for Ototoxicity From Cisplatin Chemotherapy Regimens in the Treatment of Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Otonomy, Inc. · Industry
- Sex
- All
- Age
- 6 Months – 21 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, Phase 2 study to assess the feasibility, safety and efficacy of OTO-104 given by intratympanic administration in subjects at risk for ototoxicity from cisplatin chemotherapy regimens in the treatment of cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OTO-104 | 12 mg dexamethasone administered intratympanically |
Timeline
- Start date
- 2016-11-15
- Primary completion
- 2017-09-26
- Completion
- 2017-09-26
- First posted
- 2016-12-19
- Last updated
- 2020-09-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02997189. Inclusion in this directory is not an endorsement.